Side-by-side comparison of AI visibility scores, market position, and capabilities
B2B contact intelligence platform providing verified direct dials, emails, and company data for sales and recruiting teams.
Lusha is a Tel Aviv and Boston-based B2B contact data platform that provides sales reps, recruiters, and marketers with verified direct phone numbers, email addresses, and company firmographic data for prospecting and outreach. The platform's Chrome extension enriches LinkedIn profiles, company websites, and CRM records in real time with contact information, enabling SDRs and recruiters to reach decision-makers directly rather than through gatekeepers. Lusha is built around data quality — its contact verification engine continuously validates and updates records, achieving higher connect rates than bulk-purchased contact databases. The platform integrates with Salesforce, HubSpot, Outreach, and Salesloft, feeding enriched contact data directly into existing sales workflows. Founded in 2016, Lusha reached profitability and unicorn status in 2021 after raising over $200M from investors including Bessemer Venture Partners. With over 1 million users globally, Lusha has grown into one of the largest self-serve B2B contact data platforms, competing with ZoomInfo and Apollo.io in the sales intelligence market.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.